Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

NCT01952223 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01952223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01952223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 31, 2013
Completion date
July 31, 2041
Enrollment
761 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of prostate, progression of prostate cancer